Extraction, Characterization and Therapeutic Evaluation of Seeds of Phaseolus vulgaris L. for Weight Management

Abstract

The frequency of overweight concerns and obesity is progressively growing in high-income countries in the west and low-income and middle-income countries. Those suffering from these conditions may find that taking measures to cut their carbohydrate consumption and their absorption rate is beneficial. To slow the pace at which glucose is taken into the bloodstream, blocking amylase, a key enzyme in the digestion of carbs, is highly recommended. AIs, or beta-amylase inhibitors, are chemicals found in plants that work to prevent this enzyme from doing its job. Interestingly, the common bean, or Phaseolus vulgaris, has protein-based α‐Amylase inhibitors that regulate the activity of this enzyme through protein-protein interaction. In this article, we cover the numerous extracts of common bean seeds, the protein inhibitors that those extracts include, and what the most recent research has shown about the molecular structure of those extracts and the method by which they exert their inhibitory effects. Evidence for the possible benefits of P. vulgaris protein inhibitors, including clinical research conducted on both animals and humans, is also covered in this article. However, more research is necessary to validate the therapeutic efficacy of the drugs already on the market. This research has the ability to provide a succinct review of the current state of information on P. vulgaris extract and its prospective application as a nutraceutical alternative to control possible weight gain if observed to be successful.